-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the rapid development of global cell therapy technology, the scope of cell therapy has gradually expanded, and the market demand is also growing
.
According to data, the global cell therapy market size was only US$10 million in 2017, and has grown to US$1.
1 billion in 2020.
It is expected that the market size in 2030 is expected to exceed US$20 billion
.
With the continuous expansion of the market, naturally this field has also begun to attract more and more companies to enter the market
.
Recently, Tiankeya announced that it has completed a new round of financing of more than 300 million yuan, led by AstraZeneca CICC Medical Industry Fund and CCB Investment
.
According to public information, Tiankeya was established in 2016 and is committed to the research and development and clinical development of tumor cell immunotherapy
.
This financing will accelerate the research and development of its immune cell products, expand its product line, and support the company's core products while conducting clinical development and commercialization preparations in China and the United States, as well as recruiting and building a large-scale international leading team
.
It is understood that since cell therapy technology is regarded as one of the innovative treatments that can overcome tumors, more and more pharmaceutical companies are increasing their efforts in this field in recent years
.
For example, on February 16, Saiyuan Biotechnology (Hangzhou) Co.
, Ltd.
announced the completion of a new round of financing of nearly 100 million yuan
.
It is reported that on July 16, 2021, Saiyuan Bio announced the completion of a new round of financing of tens of millions of yuan led by Kunlun Capital to promote the development of its clinical-grade immune cell production process and accelerate other innovations.
Product and pipeline development
.
After half a year, Saiyuan Bio has once again won the favor of the capital side
.
On February 16, West Lake Omi signed a memorandum of cooperation with Huanyi Bio
.
The two parties will combine their own advantages, starting from proteomics and metabolomics, combined with AI + system immune analysis technology, to jointly promote the research and development of clinical multi-omics diagnostic products in the fields of tumors and immune diseases, and provide pharmaceutical companies with biomarkers and target-oriented new drug research and development services to provide patients with AI-powered precision diagnosis and treatment solutions
.
It is worth mentioning that while the market development continues to improve, the domestic cell therapy industry has also ushered in a number of blockbuster benefits.
.
For example, some time ago, the State Food and Drug Administration publicly released the General Department of the State Food and Drug Administration to solicit opinions on the "Good Manufacturing Practice for Drugs - Cell Therapy Products Appendix (Draft for Comment)", and publicly solicited opinions from the public
.
In terms of content, the "Draft for Comments" regulates the production of cell therapy products from seven aspects: personnel, plant and facilities, supplier and supplier material management, material and product, production management, quality management, and product traceability system.
management
.
The industry pointed out that driven by this favorable policy, the domestic cell industry will become standardized and healthy, and will embrace more development opportunities in the future, and the market size is expected to further expand
.
According to statistics from Frost & Sullivan, the market size of China's cellular immunotherapy products will increase from 1.
3 billion in 2021 to 10.
2 billion in 2023, with a compound annual growth rate of 181.
5%, and is expected to reach 58.
4 billion by 2030
.
The next decade will be a period of explosive growth for the domestic cell therapy industry
.
In general, as the market prospects continue to improve, startups in the field of cell therapy are also attracting the attention of investors.
Last year, there were 59 financing events in this track in China, and the total financing exceeded the 10 billion yuan mark, and the popularity is continuing.
go higher
.
The industry believes that the gap between China's technology level and the international advanced level is not large, and it has obvious research and clinical implementation advantages.
Therefore, this field is expected to achieve "overtaking on the curve", and many companies will also usher in more opportunities
.
It is understood that AstraZeneca, which led the investment in Tiankeya, clearly stated that in the context of extremely fierce competition in the field of cell therapy, it is optimistic about the four unique features from target development to cell production created by "Tiankeya".
platform
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to data, the global cell therapy market size was only US$10 million in 2017, and has grown to US$1.
1 billion in 2020.
It is expected that the market size in 2030 is expected to exceed US$20 billion
.
With the continuous expansion of the market, naturally this field has also begun to attract more and more companies to enter the market
.
Recently, Tiankeya announced that it has completed a new round of financing of more than 300 million yuan, led by AstraZeneca CICC Medical Industry Fund and CCB Investment
.
According to public information, Tiankeya was established in 2016 and is committed to the research and development and clinical development of tumor cell immunotherapy
.
This financing will accelerate the research and development of its immune cell products, expand its product line, and support the company's core products while conducting clinical development and commercialization preparations in China and the United States, as well as recruiting and building a large-scale international leading team
.
It is understood that since cell therapy technology is regarded as one of the innovative treatments that can overcome tumors, more and more pharmaceutical companies are increasing their efforts in this field in recent years
.
For example, on February 16, Saiyuan Biotechnology (Hangzhou) Co.
, Ltd.
announced the completion of a new round of financing of nearly 100 million yuan
.
It is reported that on July 16, 2021, Saiyuan Bio announced the completion of a new round of financing of tens of millions of yuan led by Kunlun Capital to promote the development of its clinical-grade immune cell production process and accelerate other innovations.
Product and pipeline development
.
After half a year, Saiyuan Bio has once again won the favor of the capital side
.
On February 16, West Lake Omi signed a memorandum of cooperation with Huanyi Bio
.
The two parties will combine their own advantages, starting from proteomics and metabolomics, combined with AI + system immune analysis technology, to jointly promote the research and development of clinical multi-omics diagnostic products in the fields of tumors and immune diseases, and provide pharmaceutical companies with biomarkers and target-oriented new drug research and development services to provide patients with AI-powered precision diagnosis and treatment solutions
.
It is worth mentioning that while the market development continues to improve, the domestic cell therapy industry has also ushered in a number of blockbuster benefits.
.
For example, some time ago, the State Food and Drug Administration publicly released the General Department of the State Food and Drug Administration to solicit opinions on the "Good Manufacturing Practice for Drugs - Cell Therapy Products Appendix (Draft for Comment)", and publicly solicited opinions from the public
.
In terms of content, the "Draft for Comments" regulates the production of cell therapy products from seven aspects: personnel, plant and facilities, supplier and supplier material management, material and product, production management, quality management, and product traceability system.
management
.
The industry pointed out that driven by this favorable policy, the domestic cell industry will become standardized and healthy, and will embrace more development opportunities in the future, and the market size is expected to further expand
.
According to statistics from Frost & Sullivan, the market size of China's cellular immunotherapy products will increase from 1.
3 billion in 2021 to 10.
2 billion in 2023, with a compound annual growth rate of 181.
5%, and is expected to reach 58.
4 billion by 2030
.
The next decade will be a period of explosive growth for the domestic cell therapy industry
.
In general, as the market prospects continue to improve, startups in the field of cell therapy are also attracting the attention of investors.
Last year, there were 59 financing events in this track in China, and the total financing exceeded the 10 billion yuan mark, and the popularity is continuing.
go higher
.
The industry believes that the gap between China's technology level and the international advanced level is not large, and it has obvious research and clinical implementation advantages.
Therefore, this field is expected to achieve "overtaking on the curve", and many companies will also usher in more opportunities
.
It is understood that AstraZeneca, which led the investment in Tiankeya, clearly stated that in the context of extremely fierce competition in the field of cell therapy, it is optimistic about the four unique features from target development to cell production created by "Tiankeya".
platform
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
